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Abstract: The emergence of antibiotic-resistant bacteria led to an urgent need for next-generation 
antimicrobial agents with novel mechanisms of action. The use of positively charged antimicrobial 
peptides that target cytoplasmic membrane is an especially promising strategy since essential 
functions and the conserved structure of the membrane hinder the development of bacterial 
resistance. Aureocin A53- and enterocin L50-like bacteriocins are highly cationic, membrane-
targeting antimicrobial peptides that have potential as next-generation antibiotics. However, the 
mechanisms of resistance to these bacteriocins and cross-resistance against antibiotics must be 
examined before application to ensure their safe use. Here, in the model bacterium Lactococcus lactis, 
we studied the development of resistance to selected aureocin A53- and enterocin L50-like 
bacteriocins and its correlation with antibiotics. First, to generate spontaneous resistant mutants, L. 
lactis was exposed to bacteriocin BHT-B. Sequencing of their genomes revealed single nucleotide 
polymorphisms (SNPs) in the dgkB (yecE) and dxsA genes encoding diacylglycerol kinase and 1-
deoxy-D-xylulose 5-phosphate synthase, respectively. Then, selected mutants underwent 
susceptibility tests with a wide array of bacteriocins and antibiotics. The highest alterations in the 
sensitivity of studied mutants were seen in the presence of cytoplasmic membrane targeting 
bacteriocins (K411, Ent7, EntL50, WelM, SalC, nisin) and antibiotics (daptomycin and gramicidin) 
as well as lipid II cycle-blocking bacteriocins (nisin and Lcn972) and antibiotics (bacitracin). 
Interestingly, decreased via the SNPs accumulation sensitivity to membrane-active bacteriocins and 
antibiotics resulted in the concurrently increased vulnerability to bacitracin, carbenicillin, or 
chlortetracycline. It is suspected that SNPs may result in alterations to the efficiency of the nascent 
enzymes rather than a total loss of their function as neither deletion nor overexpression of dxsA 
restored the phenotype observed in spontaneous mutants. 
Keywords: aureocin A53- and enterocin L50-like bacteriocins; nisin; lactococcin 972; cell envelope-
acting antibiotics; bacteriocins and antibiotic resistance; lipid metabolism; Lactococcus lactis 
 
1. Introduction 
The cell envelope is one of the most important cellular structures that gives a cell the 
shape, protects it from the environment, acts as a diffusion barrier and communication 
interface, and allows for cellular growth and division [1]. There are two groups of bacteria, 
Gram-positive and Gram-negative, that have fundamentally different cell envelopes. Both 
of them contain a cytoplasmic membrane composed of double layers of lipids such as 
phosphatidylglycerol, diphosphatidylglycerol (cardiolipin), and 
phosphatidylethanolamine, which are present in different proportions depending on the 
bacteria species [2]. The cell membrane of Gram-negative bacteria is surrounded by a cell 
wall composed of a thin layer of peptidoglycan and an outer membrane containing 
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lipopolysaccharides. The Gram-positive bacteria do not contain a protective outer 
membrane, but their cell wall is much thicker. It is a multilayered, net-like structure 
composed of peptidoglycan and teichoic acids that can be either anchored to the cell 
membrane (lipoteichoic acids) or covalently bound to the peptidoglycan (wall teichoic 
acids) [1]. The bacterial cell envelope and its biosynthetic pathways are important targets 
for many antimicrobial agents such as antibiotics and bacteriocins, especially in Gram-
positive bacteria that possess a cell envelope of two functional layers only. 
Most of the conventional cell envelope targeting antibiotics inhibit different steps of 
cell wall biosynthesis. They can act on the intracellular targets such as fosfomycin that 
enters the cells through membrane channels/transporters and binds to MurA enzyme 
inhibiting the first step of peptidoglycan synthesis [3]. However, antibiotics that achieved 
the biggest clinical success act on the extracellular targets binding to important cell wall 
precursors or enzymes that process them [4]. The bacterial lipid II cycle constitutes a prime 
target for antibiotics. Ramnoplanin, vancomycin, and teicoplanin bind to the different 
moieties of lipid II [5,6], whereas bacitracin complexes with divalent metal ions, bind to 
undecaprenyl-pyrophosphate (UPP) and prevent its dephosphorylation to undecaprenyl 
phosphate (UP) [7]. β-lactams such as carbenicillin operate outside of the lipid II cycle by 
binding and inhibiting the activity of penicillin-binding proteins (PBPs), transpeptidases 
involved in the transpeptidation (cross-linking) step of the peptidoglycan synthesis [8]. 
Unfortunately, the long-term and improper use of antibiotics led to the emergence of 
antibiotics resistant bacteria, which is one of the biggest threats to global healthcare 
nowadays. Therefore, next-generation antibiotics with novel mechanisms of action are 
urgently needed. The cytoplasmic membrane is a particularly promising target for novel 
antibiotics. Its essentiality and highly conserved structure is a challenge for bacteria to 
modify it without substantial loss of function and, therefore, the acquisition of resistance 
is difficult [9]. A novel generation of membrane-targeting antibiotics includes daptomycin 
and gramicidin. Daptomycin is a front-line agent in the treatment of infections caused by 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus 
faecium (VRE). Daptomycin complexes with calcium ions form micelles and then interact 
with anionic phosphatidylglycerol and disrupt membrane integrity [10]. Gramicidin 
forms dimeric channels in the membrane, facilitates diffusion of water and a selection of 
monovalent cations, and disrupts cellular ionic homeostasis [11]. 
In recent years, the use of antimicrobial peptides or proteins of bacterial origin, 
known as bacteriocins, as next-generation antibiotics has been intensively studied. 
Additionally, among bacteriocins, those targeting cell wall biosynthesis and cytoplasmic 
membrane can be distinguished. The most extensively studied cell envelope targeting 
bacteriocins are nisin and nisin-like lantibiotics. They are posttranslationally modified 
peptides with lanthionine and methyllanthionine residues forming tioether rings. They 
have a unique mode of action as they form a complex with a moiety of lipid II thereby 
inhibiting peptidoglycan synthesis and then incorporate into cytoplasmic membrane and 
form pores [12]. Lactococcin 972 (Lnc972) is the only known so far non-lantibiotic 
bacteriocin that targets lipid II and inhibits peptidoglycan synthesis but it does not form 
pores [13]. Amongst membrane-targeting bacteriocins, families of aureocin A53- 
(AurA53-) and enterocin L50- (EntL50-) like bacteriocins are currently getting attention 
because of their unique structures and biosynthetic mechanisms [14,15]. The first family 
consists of AurA53 [16], BHT-B [17], lacticin Q (LacQ) [18], lacticin Z (LacZ) [19], 
epidermicin NI01 (EpiNI01) [20], and lactolisterin BU (LliBU) [21]. The latter consists of 
EntL50 (EntL50A and EntL50B) [22], enterocin 7 (Ent7; Ent7A and Ent7B) [23], weissellicin 
M (WelM), and weissellicin Y (WelY) [24]. They are non-lantibiotic, leaderless bacteriocins 
with a highly cationic, hydrophobic character and broad spectra of antimicrobial activity. 
They display sequence homology within their families and all have similar saposin-like 
fold [15]. Saposins are a group of lipid-interacting human proteins with a structure of four-
five α-helices forming a hydrophobic core (saposin fold) [25]. Saposin-like fold refers to a 
structure of three-four α-helices with a highly cationic, hydrophilic surface and a 
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hydrophobic core that enables peptide–lipid interactions in the cell membrane [15,26,27]. 
Although all AurA53- and EntL50-like bacteriocins are thought to disrupt bacterial 
membranes in the absence of a specific receptor, the mechanism of membrane disruption 
by individual bacteriocins may differ. AurA53 acts through generalized membrane 
destruction rather than pore formation [28], while LacQ forms huge toroidal pores and 
causes accumulation of lethal hydroxyl radicals [29,30]. The mechanism of action of other 
AurA53- and EntL50-like bacteriocins remains to be elucidated. 
To protect the essential and vulnerable structure of the cell envelope, bacteria have 
evolved complex regulatory networks that orchestrate cell envelope stress response. In 
Gram-positive Firmicutes, the BceRS- and LiaRS-like two-component regulatory systems 
(TCSs) are the core of cell envelope stress response. They mediate response to a specific 
compound or a group of related compounds (BceRS-like) as well as a wide array of cell 
envelope-damaging agents (LiaRS-like) [1]. They contain membrane-bound histidine 
kinases (HKs) and cytoplasmic response regulators (RRs). Typically, BceS- and LiaS-like 
HKs lack extracellular sensory domains and form sensory complexes with BceAB-like 
membrane-localized ABC transporters or LiaF-like membrane-anchored inhibitor 
proteins, respectively. The sensory complexes are responsible for sensing the stimuli and 
transferring a signal to the cognate BceR- and LiaR-like RRs that orchestrate the 
expression of genes responsible for maintaining cell integrity over a stressor presence. The 
genes encoding ABC transporters involved in the detoxification, proteins of the phage 
shock protein (Psp)-like response or proteins involved in the cell wall and cytoplasmic 
membrane synthesis and modification are among the most often regulated genes [31]. 
Modifications of the cell envelope composition are probably the most important 
mechanism of resistance since they often result in simultaneously decreased sensitivity to 
different antimicrobial agents including antibiotics and bacteriocins. One of the most 
important cell wall modifications is BceR-dependent D-alanylation of teichoic acids due 
to overexpression of the dlt operon. It decreases the negative charge of the cell wall making 
cells more resistant to positively charged antimicrobials. Additionally, LiaR-dependent 
increased peptidoglycan polymerization due to overexpression of the pbp2 gene results in 
the cell wall thickening and increased antimicrobial resistance. The most important 
cytoplasmic membrane modification is a BceR-dependent lysination of the 
phosphatidylglycerol by the multiple peptide resistance factor (MprF) that results in the 
incorporation of the positive charge into phosphatidylglycerol [31]. Some less studied 
modifications of the cytoplasmic membrane include a lower amount of the saturated fatty 
acid and less elongated fatty acids due to lower expression of the fab operon [32], increased 
level of phosphatidylglycerol over cardiolipin [33], decreased level of the anionic 
phospholipids (phosphatidylglycerol and cardiolipin), and increased level of zwitterionic 
phosphatidylethanolamine [34,35]. The role of BceRS- and LiaRS-like TCSs in resistance 
to cell envelope targeting antibiotics is fairly well documented in many reviews on this 
topic [1,31,36]. However, among cell envelope-acting bacteriocins only nisin and Lcn972 
were shown to induce stress response regulatory systems [32,37]. The mechanisms of 
resistance to other cell envelope targeting bacteriocins and the possible cross-resistance 
with antibiotics are not known. Understanding the biochemical and genetic basis of 
resistance to membrane-targeting AurA53- and EntL50-like bacteriocins is of great 
importance to allow the safe application of these bacteriocins as next-generation 
antibiotics. 
Here we studied the genetic basis of resistance to the AurA53- and EntL50-like 
bacteriocins and a broad array of antibiotics with distinct mechanisms of action. First, we 
generated spontaneous resistant mutants by exposing highly sensitive Lactococcus lactis 
LMGT 3419 to BHT-B. By the use of genome sequencing, we identified responsible for the 
resistant phenotype non-synonymous single mutations within the dgkB (yecE) and dxsA 
genes involved in the lipid metabolism. Then, we tested the susceptibility of selected 
mutants to other AurA53- and EntL50-like bacteriocins including three functional (Ent7, 
EntL50, and WeiM) and two putative (K411 and SalC) representatives, nisin, Lcn972 and 
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a wide array of antibiotics. This revealed that common mechanisms involving 
modification of the cell wall and cytoplasmic membrane may be involved in the resistance 
to tested bacteriocins and certain antibiotics, mainly those cell envelope-active. Moreover, 
we found here that gaining resistance to selected antimicrobials may increase sensitivity 
to some antibiotics, such as bacitracin, carbenicillin, and chlortetracycline. 
2. Results 
2.1. Accumulation of L. lactis BHT-B Resistant Mutants 
Strains sensitive to BHT-B belong to the species Micrococcus luteus, Lactococcus lactis, 
Streptococcus pyogenes, and S. equisimilis [17]. L. lactis, formerly grouped into the genus 
Streptococcus [38], is a close relative to the BHT-B producing Streptococcus rattus BHT, and 
also is a model bacterium with a well-developed research tool-box dedicated to genetic 
analyses, therefore, was selected here to generate spontaneous mutants resistant to BHT-
B. By growing the cells in the presence of bacteriocin in the solid medium, we isolated five 
independent L. lactis mutants (MUT70, MUT71, MUT72, MUT73, MUT78) with 4-fold 
decreased sensitivity to BHT-B in comparison with the parental strain L. lactis LMGT 3419 
(minimum inhibitory concentration MIC50 = 6.3 μg/mL) (Table 1). Amidst these resistant 
mutants, L. lactis MUT78 was used for further mutagenization and, as the result, the 
second-generation L. lactis MUT78.2 mutant was obtained and characterized to have 2-
fold and 8-fold decreased sensitivity in comparison with the parental L. lactis MUT78 and 
wild-type L. lactis LMGT 3419, respectively (Table 1). 
Table 1. Features of spontaneous Lactococcus lactis LMGT 3419 mutants resistant to BHT-B. 
Mutant Sensitivity 
Decrease * 
Mutation in Nucleotide 
Sequence 
Mutation in Amino 
Acid Sequence 
Potential Function 
MUT70 4× 286G→T in dgkB (yecE) Asp96→Tyr Diacylglycerol kinase 
MUT72 4× 163G→T in dgkB (yecE) Glu55→STOP Diacylglycerol kinase 
MUT71, MUT73, 
MUT78 4× 1469C→G in dxsA Ser490→STOP 1-deoxy-D-xylulose 5-phosphate (DXP) synthase 
MUT78.2 8× 1469C→G in dxsA; 780T→G in ysaB; 328G→T in ynhD Ser490→STOP;Tyr260→STOP; Glu110→STOP DXP synthase; ABC transporter permease; 
hypothetical protein 
* In comparison to the wild-type strain L. lactis LMGT 3419. 
2.2. Identification of Genes Altered by Mutations in the BHT-B Resistant Mutants 
To identify genetic changes responsible for the development of resistance to BHT-B, 
genomes of all six spontaneous resistant mutants, as well as wild-type were isolated and 
sequenced. Subsequently, the whole-genome sequence reads from the resistant mutants 
were compared with the assembled reference genome to identify single nucleotide 
polymorphisms (SNPs). Mutations with low frequency or localized in low-coverage 
regions were excluded from further analysis. Two resistant mutants (MUT70 and MUT72) 
contained missense or nonsense mutations in the yecE gene encoding lipid kinase that 
resulted in the Asp96Tyr substitution or very early termination of translation after Thr54 
of the YecE protein, respectively (Table 1). Three other mutants (MUT71, MUT73, MUT78) 
harbored a single and identical nonsense mutation in the dxsA gene encoding 1-deoxy-D-
xylulose 5-phosphate (DXP) synthase (DXS). The effect of the mutation was a premature 
truncation of the DXP synthase at Ser490 position (Table 1). The second-generation 
MUT78.2 mutant was of special interest due to two, additional to dxsA, nonsense 
mutations in the ysaB and ynhD genes. Mutations resulted in the premature truncation of 
the encoded ATP-binding cassette (ABC) transporter permease YsaB and hypothetical 
protein YnhD (Table 1). More precise homology searches showed that YnhD shares 99.5% 
and 94.7% identity to, respectively, lactococcal 5-bromo-4-chloroindolyl phosphate 
Int. J. Mol. Sci. 2021, 22, 1014 5 of 19 
 
 
hydrolysis protein (NCBI RefSeq WP_081042512.1) and XpaC-like protein 
(WP_011835023.1). 
2.3. Analysis of Mutations in the yecE and dxsA Genes 
To analyze the loci and therefore potential downstream effects of the mutations in 
the yecE and dxsA genes on the structure and function of the encoded protein, we 
predicted their structures using structural templates from the Protein Data Bank archive. 
YecE shares 45.54% and 33% identity with the used templates of the highest significance 
DgkB diacylglycerol kinases from S. aureus MRSA252 and Enterococcus faecalis V583, 
respectively. Due to this homology, from this point of this work, YecE will be named DgkB 
and accordingly, its encoding gene, dgkB. The tertiary structure of DgkB is of two-domain 
architecture with α/β-fold and an active site in a cleft between the two domains (Figure 
1A). Based on the sequences and structures homology, we predicted the localization of 
three conserved nucleotide-binding motifs that are present in the N-terminal 
diacylglycerol kinase catalytic domain of DgkB, and define members of the soluble 
diacylglycerol kinase superfamily (Pfam accession no. PF00781) [39]. Importantly, both 
amino acids changed by mutations were localized in the N-terminal catalytic domain and, 
the substituted by missense mutation Asp96 (equivalent to Asp97 in S. aureus), was a part 
of the third conserved motif forming DgkB active site (Figure 1B). 
DxsA shares 34.25% and 33.78% identity with used as templates of the highest 
significance DXP synthases from Deinococcus radiodurans R1 and Escherichia coli K12, 
respectively. DxsA contains three domains with central, mostly parallel β-sheets (five in I 
and III domain, and six in II domain) surrounded by α-helices (Figure 2A) and conserved 
amino acids forming DxsA active site [40]. Amino acid changed by nonsense mutation 
was not conserved among DXP synthases and was not localized nearby conserved amino 
acid residues forming an active site. While the active site was localized at the interface 
between the I and II domains, the mutated amino acid was localized at the beginning of 
the III domain of DxsA (Figure 2B). Therefore, nonsense mutation resulted in the 
production of truncated protein containing two domains only. Amino acid substitution in 
the DgkB active site, as well as the production of DxsA devoid of its C-terminal domain, 
could lead to significant changes in the activity of these proteins including their 
inactivation or induction of their activity.




Figure 1. (A) The predicted tertiary structure of L. lactis LMGT 3419 DgkB (YecE). (B) Alignment of primary and secondary structures of diacylglycerol kinases from 
L. lactis LMGT 3419, Staphylococcus aureus MRSA252 and Enterococcus faecalis V583. Stars, colons, and dots indicate fully, high, and low consensus residues, 
respectively. Conserved and homologous amino acids are highlighted in red and yellow, respectively. Amino acids changed by nonsense and missense mutations 
are highlighted in light and dark grey, respectively. Triangles indicate three conserved motifs that participate in the nucleotide-binding in S. aureus MRSA252. 
Squares indicate a divalent cation binding site in S. aureus MRSA252. Secondary structure elements are indicated with H (α-helix) and S (β-strand). Structural 
domains I and II are distinguished with blue and light green, respectively. 




Figure 2. (A) Predicted tertiary structure of L. lactis LMGT 3419 DxsA. (B) Alignment of primary and secondary structures of DXP synthases from L. lactis LMGT 
3419, D. radiodurans R1 and E. coli K12. Stars, colons, and dots indicate fully, high, and low consensus residues, respectively. Conserved and homologous amino 
acids are highlighted in red and yellow, respectively. Amino acid changed by nonsense mutation is highlighted in grey. Triangles indicate residues in the active site 
of D. radiodurans R1 and E. coli K12 DXP synthases. The secondary structure elements are indicated with H (α-helix) and S (β-strand). Structural domains I, II, and 
III are distinguished with blue, dark green, and light green, respectively. 
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2.4. Effect of Mutations on the Sensitivity to Bacteriocins 
To examine an effect of mutations on the sensitivity to different cell envelope 
targeting bacteriocins, we tested the activity of membrane-disrupting AurA53- and 
EntL50-like bacteriocins (K411, Ent7, EntL50, WelM, and SalC), inhibiting cell wall 
synthesis Lcn972 and nisin against four representatives of L. lactis mutants (MUT70, 
MUT72, MUT78, MUT78.2). In comparison with the wild-type L. lactis LMGT 3419, all 
BHT-B-resistant mutants showed also decreased sensitivity to other bacteriocins tested. 
The level of sensitivity differed depending on the mutated gene. Mutations within dgkB 
(strains MUT70 and MUT72) had the lowest impact on the sensitivity to bacteriocins since 
only a 2–4-fold increase in MIC50 values was observed in most cases (Table 2). Mutation 
in dxsA (MUT78) resulted in the 4–8-fold MIC50 increase to all bacteriocins apart from 
EntL50 and nisin, whose presence elevated this ratio to over 32 (Table 2). Multiple 
mutations in MUT78.2 led to the highest increase of MIC50 values such as 8–16-fold to 
most bacteriocins except for Ent7, EntL50 and nisin in presence of which this ratio elevated 
to 32 (Ent7 and nisin) or 128 (EntL50) (Table 2). 
Table 2. Level of resistance of L. lactis LMGT 3419 wild-type and its mutants to aureocin A53-like and enterocin L50-like 
bacteriocins, nisin, lactococcin 972, and antibiotics. Colored resistance scale represents rounded fold-change of MIC 
(minimum inhibitory concentration) value relative to wild-type L. lactis LMGT 3419. Significantly increased or decreased 
diameters of bacterial growth inhibition are highlighted with vivid green or red, respectively. 
Antimicrobial Agent 
LMGT 3419 MUT70  MUT72  MUT78 MUT78.2 MUT80  MUT84 MUT85 







 MIC50 [μg/mL] 
K411 3.2 6.4 6.4 12.5 >25 3.2 12.5 6.3 
BHT-B 6.3 25 25 25 >25 6.3 25 12.5 
Ent7 0.2 0.4 0.4 1.6 6.4 0.2 0.4 0.2 
EntL50 0.2 0.8 0.8 6.4 25 0.4 0.8 0.8 
WelM 2.4 18.8 18.8 18.8 >25 2.4 >25 25 
SalC 6.3 12.5 12.5 >25 >25 6.3 25 12.5 
Nisin 0.47 1.9 1.9 >15 >15 0.47 >15 15 
Lcn972 0.4 1.6 1.6 3.2 >3.2 0.4 3.2 1.6 
 MIC [μg/mL] 
Bacitracin 12 4 3 4–6 2 12 6 6 
Daptomycin 0.094 1 0.5 1 2 0.064 0.5 0.5 
Gramicidin 0.023 0.188 0.188 >0.75 0.75 0.012 0.75 0.75 
Gentamicin 2 12 8–12 8 12–16 2 6 6 
Kanamycin 12 32 32 32 32 6 32 32 
Streptomycin 24 48 48 48 64 12 64 64 
Vancomycin 0.38 1 0.5–0.75 1 1.5 0.5 1 1 
Fosfomycin 384 >1024 >1024 1024 >1024 >1024 384 384 
 Diameter [mm] 
Carbenicillin 28 31 31 32 33–34 29 33 34 
Chlortetracycline 21 29 32 33 32 24 14 * 15 * 
L. lactis LMGT 3419 mutants did not exhibit significant changes in the sensitivity to antibiotics such as inhibitors of cell 
wall biosynthesis (amoxicillin, ampicillin, cefuroxime, and cephalothin), inhibitors of DNA biosynthesis (ciprofloxacin 
and norfloxacin), inhibitors of protein biosynthesis (chloramphenicol, clindamycin, and erythromycin), inhibitor of folate 
biosynthesis (trimethoprim), inhibitor of DNA, RNA and protein biosynthesis, respiration, and pyruvate metabolism 
(nitrofurantoin). * The significant decrease of sensitivity observed here is due to the tetR resistance gene present in pIBB-
JZK. 
Sensitivity scale: 6× 4× 3× 2× 2× 4× 8× 16× ≥32× 
Fold of increased sensitivity←  →  Fold of decreased sensitivity 
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2.5. Effect of Mutations on the Sensitivity to Antibiotics 
To examine the effect of mutations on the sensitivity to antibiotics, L. lactis MUT70, 
MUT72, MUT78, MUT78.2 underwent susceptibility tests with a wide array of antibiotics 
acting on different cellular targets. We included the membrane-disrupting ones 
(daptomycin and gramicidin), inhibiting cell wall synthesis (amoxicillin, ampicillin, 
bacitracin, carbenicillin, cefuroxime, cephalothin, fosfomycin, and vancomycin), 
inhibiting DNA synthesis (ciprofloxacin and norfloxacin), inhibiting protein synthesis 
(chloramphenicol, chlortetracycline, clindamycin, erythromycin, gentamicin, kanamycin, 
streptomycin, and tetracycline), inhibiting folate synthesis (trimethoprim), and inhibiting 
respiration and pyruvate metabolism (nitrofurantoin). In comparison to the wild-type 
strain, all tested mutants exhibited increased sensitivity to bacitracin, carbenicillin, or 
chlortetracycline. The level of gained sensitivity depended on the mutated gene and, in 
the case of bacitracin, was most pronounced after mutation of dgkB (MUT72) or dxsA-ysaB-
ynhD- (MUT78.2), reaching 4–6-fold change of MICs (Table 2). In the presence of 
carbenicillin or chlortetracycline the most significant increase of sensitivity was triggered 
by multiple mutations within MUT78.2 and also by a single mutation in dxsA (MUT78). 
Contrary, in the presence of daptomycin, gramicidin, gentamicin, kanamycin, 
streptomycin, vancomycin, or fosfomycin, MIC values increased, indicating induction of 
mutants’ resistance to these antimicrobials. In this case, the most significant changes in 
the MIC values (>8–≥32-fold) occurred in the presence of daptomycin or gramicidin and 
considered mutants MUT78 and MUT78.2, both harboring mutated dxsA. Cross-resistance 
of mutants to gentamicin, kanamycin, streptomycin, vancomycin, or fosfomycin was on 
the lower level and reached mostly 2–4-fold of decreased sensitivity (Table 2). Finally, no 
significant changes in MICs of all remaining antibiotics tested were observed between the 
wild-type and mutants. 
2.6. The Effect of Deletion or Overexpression of the dxsA Gene 
The SNP occurring in dxsA reduced the susceptibility of the MUT78 strain to cell 
envelope-acting antimicrobials indicating its important role in the response to the 
presence of these compounds. However, this point mutation did not remove the DxsA 
protein completely but merely truncated its C-terminal end (Figure 2), which did not 
necessarily result in its inactivation. To examine the effect of bacteriocins and antibiotics 
on cells fully devoid of dxsA, first, we deleted it from the genome of L. lactis LMGT 3419. 
In comparison with the wild-type strain, the obtained deletion mutant L. lactis MUT80 
showed no differences in the sensitivity to AurA53- and EntL50-like bacteriocins, nisin 
and Lcn972 (Table 2). A minor, at the most 2-fold increase of L. lactis MUT80 sensitivity to 
gramicidin, kanamycin, and streptomycin and 3-fold decrease of sensitivity to fosfomycin 
were observed (Table 2). 
To examine the effect of bacteriocins and antibiotics on cells overexpressing the dxsA 
gene, we cloned it in the pIBB-JZK vector under the control of a strong cellobiose-
responsive promoter PptcB (pIBB-JZK:PptcB:dxsA) in L. lactis LMGT 3419. In comparison 
to the wild-type L. lactis LMGT 3419 and MUT82 carrying an empty plasmid, obtained 
this way L. lactis MUT83 showed no differences in the sensitivity to all tested compounds 
(data not shown). On the other hand, the same recombinant construct pIBB-
JZK:PptcB:dxsA, complemented partially the point mutation of dxsA present in MUT78. 
Obtained in this way L. lactis MUT85 had a reduced level of resistance to almost all 
bacteriocins when compared to the strain carrying the empty pIBB-JZK (L. lactis MUT84) 
as well as parental L. lactis MUT78. However, the MIC50 values of L. lactis MUT85 did not 
fully recover to those of the wild-type strain, which indicates only a partial reversion to 
the wild-type phenotype. Moreover, this effect was observed only in the case of 
bacteriocins, whereas the level of L. lactis MUT85 resistance to antibiotics remained mostly 
unchanged when compared to dxsA- strains (MUT78 and MUT84) (Table 2). 
  




Nowadays, an increasing number of infections caused by multidrug-resistant 
bacteria are reported. To treat them, next-generation antibiotics with novel mechanisms 
of action are needed. Positively charged antimicrobial peptides have become a promising 
group of antimicrobials due to their ability to kill bacteria via nonreceptor mediated 
disruption of the negatively charged cytoplasmic membrane [9]. Although the 
development of resistance to such peptides is difficult and complex, it is also inevitable. 
Therefore, in-depth studies are needed to understand and limit this phenomenon. Here, 
we studied the genetic basis of resistance to cationic, membrane targeting AurA53- and 
EntL50-like bacteriocins. Among them, for this study, we selected four functional (BHT-
B, Ent7, EntL50, WelM) and two putative ones (K411 and SalC; UniProt accession numbers 
Q576C5 and A0A089RZU, respectively). L. lactis is a Gram-positive cocci and, due to its 
relatedness to some pathogens, sensitivity to many antibacterial compounds, as well as 
well-developed research tool-box dedicated to genetic analyses, this species is a model 
microorganism for research on resistance mechanisms. Moreover, since L. lactis is 
standardly used in food-processing industry, it may also acquire resistance to 
antimicrobial compounds added to food or produced by the bacteria present in these 
products. By growing sensitive L. lactis in the presence of BHT-B, we generated 
spontaneous resistant mutants, which revealed also cross-resistance to all other studied 
here bacteriocins as well as most of the cell-envelope targeting antibiotics. Interestingly, 
this time we were able to obtain mostly 2–32-fold more resistant mutants, whereas, in our 
previous research on the mechanisms of resistance to bacteriocins known as garvicins, we 
generated over 1024-fold more resistant mutants [41,42]. This difference may be due to 
the different targets of attack and mechanisms of action for these two groups of 
bacteriocins. While the receptor for garvicins is a membrane-located protein complex 
(mannose–phosphotransferase system; Man-PTS) [41,42], the AurA53- and EntL50-like 
bacteriocins do not have a specific receptor and act by inserting in and destroying the cell 
membrane [9,28–30]. Consequently, the mechanisms of resistance to these two groups of 
bacteriocins also differ. Whereas resistance to garvicins is achieved by simply inactivating 
or modifying the protein target of their attack [41,42], we speculate here that the 
mechanism for the AurA53- and EntL50-like bacteriocins may be the modification of the 
cell membrane lipid composition and/or cell wall structure. Specifically, we found that 
resistance to AurA53- and EntL50-like bacteriocins is due to mutations in the dgkB and 
dxsA genes. DgkB shares significant identity with soluble diacylglycerol kinases from S. 
aureus MRSA252 and E. faecalis V583 and owns conserved nucleotide-binding motifs that 
define members of the soluble diacylglycerol kinase superfamily. DgkB is a key enzyme 
in lipid metabolism that catalyzes the ATP-dependent phosphorylation of diacylglycerol 
(DAG) to phosphatidic acid. In bacteria, a large amount of DAG is formed by the 
hydrolysis of membrane phosphatidylglycerol in the process of lipoteichoic acids 
biosynthesis. Therein, phosphatidylglycerol is extensively used as the source of sn-1-
glycerol-P headgroup. The synthesis of a single lipoteichoic acid requires the addition of 
14 to 33 sn-1-glycerol-P headgroups and the removal of the headgroup from 
phosphatidylglycerol results in the formation of DAG. DgkB recycles DAG into the 
phospholipids biosynthetic pathway and thus prevents its accumulation in the bacterial 
cell membranes [39]. Although DgkB is an essential protein in bacteria, Jerga et al. [43] 
performed conditional inactivation of dgkB in B. subtilis and showed that it leads to the 
cessation of lipoteichoic acid formation, accumulation of DAG and eventual loss of cells 
viability. Our analysis showed that changed by missense mutation Asp96 (equivalent to 
Asp97 in S. aureus) may be a key residue of the lactococcal DgkB active site since in S. 
aureus, which possesses prototypical diacylglycerol kinase of Gram-positive bacteria, 
Asp97 coordinates Mg2+ via water molecules and is involved in the ATP binding forming 
the top of the nucleotide-binding site [39]. Identified in this study substitution of 
negatively charged, polar Asp with aromatic, partially hydrophobic Tyr may have a 
significant impact on the structure and function of the DgkB. In this study, we did not 
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delete dgkB, as inactivation of DkgB is lethal due to accumulation of DAG or absence of 
lipoteichoic acids [43], and accordingly, it can be assumed that SNPs that arose in 
lactococcal genome did not abolish but rather modified the activity of this enzyme. 
Our thorough analysis of the scientific literature shows a lack of data linking the dgkB 
gene with bacteriocin resistance to date. However, mutations within the gene encoding 
DgkB of S. mutans were previously identified in the spontaneously arising mutants with 
reduced susceptibility to chlorhexidine, a cationic antiseptic that targets bacterial cell 
membrane [44]. Similar to our study, almost all of these mutants displayed cross-
resistance to daptomycin and increased sensitivity to bacitracin. Interestingly, 
spontaneous mutations occurred over the length of the dgkB gene and always resulted in 
amino acid substitutions, whereas one of the two SNPs found in this study resulted in a 
premature stop codon. The authors speculated that the mutations influenced the 
efficiency of the enzyme rather than caused its inactivation since although dgkB is an 
essential gene in S. mutans [45], no growth defects were observed in the S. mutans mutants 
expressing mutated dgkB [44]. This is also in line with our research hypothesis since SNPs 
that occurred in dgkB of L. lactis maintained the respective mutants viable. S. mutans dgkB 
mutants exhibited distinct amounts of lipoteichoic acid produced [44] and thus, it is 
tempting to speculate that SNPs in dgkB of L. lactis may also alter their accumulation in 
the cell wall. The modified amount of negatively charged lipoteichoic acids may be 
responsible for the changes in accessibility to the target molecules i.e., cytoplasmic 
membrane or lipid II cycle intermediates and/or influence the charge of the cell wall. The 
reduction of the negative charge of the cell wall could make cells more resistant to 
positively charged antimicrobials such as AurA53- and EntL50-like bacteriocins, 
gramicidin, nisin, Lcn972, and vancomycin. This mechanism seems more likely as it 
explains why spontaneous mutants exhibit also decreased sensitivity to positively 
charged aminoglycosides [46,47] such as streptomycin, kanamycin, and gentamicin and 
increased sensitivity to negatively charged carbenicillin and chlortetracycline. 
Nevertheless, further studies are needed to fully understand the mechanisms of DgkB-
mediated resistance. 
DxsA is a crucial enzyme in the isoprenoids biosynthesis. Isoprenoids are one of the 
larger groups of natural compounds that occur in all domains of life and take part in many 
important physiological processes. Well-known examples of bacterial isoprenoids include 
menaquinones (vitamin K2) and ubiquinones (coenzyme Q) that are involved in the 
production of energy through the electron transport chain [48], bactoprenols that act as 
membrane lipid anchors in the biosynthesis of peptidoglycan [49], and hopanoids that 
function as analogs of cholesterol in bacterial membranes [50]. All isoprenoids are 
synthesized from two precursors—isopentenyl pyrophosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP). DxsA catalyzes the first and the rate-limiting step in the non-
mevalonate pathway for the biosynthesis of IPP and DMAPP that is the formation of 1-
deoxy-D-xylulose 5-phosphate (DXP) from D-glyceraldehyde 3-phosphate and pyruvate 
[40,51,52]. Identified here, a nonsense mutation within the dxsA gene resulted in the 
production of a truncated protein with the preserved active site. As neither dxsA deletion 
nor overexpression recreated the changes in susceptibility to any of the antimicrobials that 
we observed in the spontaneous mutant, we assume that the DxsA enzyme in MUT78 is 
still functional. SNP that occurred in dxsA may result in the specific modification of the 
nascent protein function leading to the changes in the phenotype of the mutant. The effect 
of the modified DxsA on the change of mutant resistance persisted even in the presence 
of its wild copy in MUT85, which additionally confirms that truncated DxsA is active and 
efficiently performs its protective function. Due to the large number and diversity of 
bacterial isoprenoids, it is difficult to judge how a mutation in dxsA may be responsible 
for changes in sensitivity to studied bacteriocins and antibiotics. Anyway, the highest 
decrease in sensitivity was observed in the presence of membrane-active antimicrobials 
(AurA53- and EnL50-like bacteriocins, nisin, daptomycin, and gramicidin) therefore, 
modifications of the cell membrane seem to be the most likely mechanism of resistance. 
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Hopanoid lipids are some of the most ubiquitous isoprenoids responsible for the cell 
membrane fluidity and permeability, thereby cell sensitivity to antibiotics and other stress 
conditions [50]. They can intercalate into a lipid bilayer, order saturated lipids and form a 
liquid-ordered phase in bacterial membranes. The presence of hopanoid lipids condenses, 
thickens, and decreases the fluidity and permeability of bacterial membranes [53]. 
Hopanoid-deficient mutants have been shown to display increased sensitivity to 
antibiotics such as polymyxin B, colistin (polymyxin E), erythromycin or 
chloramphenicol, detergents, and stress conditions [50,54–56]. Mutation within dxsA may 
boost hopanoids synthesis thereby membrane stability and integrity to counteract the 
disrupting activity of membrane-active antimicrobials. 
In comparison to mutants carrying single mutations, L. lactis MUT78.2 with multiple 
SNPs had the highest level of changed susceptibility to studied antimicrobials suggesting 
that resistance mechanisms may accumulate. In L. lactis MUT78.2, in addition to a single 
SNP in dxsA, two additional mutations in the ysaB and ynhD genes were identified. 
Encoded by ysaB, an ABC transporter permease YsaB was previously shown to be part of 
the Bce-like stress response regulatory system that is involved in resistance to nisin and 
Lcn972. In L. lactis, it is composed of ABC transporter YsaCB and two-component 
regulatory system KinG-LlrG, while the latter consists of HK KinG and RR LlrG [32,37]. 
The primary role of this detoxification module is to mediate resistance to peptide 
antibiotic bacitracin. The BceAB transporter, which is a B. subtilis YsaCB homolog, binds 
to the bacitracin-UPP complex and releases UPP from the grip of the bacitracin, protecting 
the cell wall synthesis. At the same time, BceAB forms a sensory complex with BceS HK 
that uses a flux-sensing mechanism to monitor the detoxification capacity of BceAB and, 
if necessary, phosphorylates BceR to activate expression of the bceAB genes [57,58]. In 
accordance, truncation of lactococcal YsaB permease in MUT78.2 significantly increased 
mutant’s sensitivity to bacitracin. Point mutations in the ysaCB-kinG-llrG were speculated 
to activate expression of LlrG-regulated genes that in turn confer resistance to Lcn972 [59]. 
We anticipate that a similar mechanism may be involved in resistance to AurA53- and 
EntL50-like bacteriocins. BceR of B. subtilis regulates only the expression of bceAB genes, 
however, many BceRS-like TCSs regulate the expression of other genes such as mprF and 
dltABCDE [31]. As these genes lower the negative cell surface charge by modifying the 
cell wall and cytoplasmic membrane components [31], it is tempting to speculate that they 
are also regulated by the lactococcal KinG-LlrG TCS, which would explain decreased 
sensitivity of MUT78.2 to positively charged bacteriocins, daptomycin-calcium 
complexes, vancomycin and aminoglycosides, and increased sensitivity to negatively 
charged carbenicillin and chlortetracycline. Another gene of L. lactis MUT78.2 mutated in 
response to BHT-B encodes YnhD, a hypothetical protein nearly identical with lactococcal 
XpaC-like and 5-bromo-4-chloroindolyl phosphate hydrolysis proteins. Since its mutation 
was accompanied by SNPs in ysaB and dxsA genes, its direct role in resistance to tested 
antimicrobials remains uncertain, however, based on some previous reports we can 
anticipate that it also protects cells from some of the antimicrobials tested in this study. 
For example, the ynhD gene was found to be upregulated in the nisin resistant L. lactis 
cells where YnhD was annotated as a tellurite resistance protein [32]. Overexpression of 
tellurite resistance-related proteins (YceGHI) contributed to nisin resistance of B. subtilis 
[60]. Moreover, a gene encoding the XpaC-like protein was upregulated in the hBD3-
treated S. aureus cells [61] and amino acid substitution within XpaC was found in 
daptomycin-resistant E. faecium [62]. However, further studies on the ynhD gene including 
its deletion and overexpression are required to evaluate its direct role in the resistance to 
AurA53- and EntL50-like bacteriocins and its interconnection with increased resistance or 
sensitivity to certain antibiotics. 
Altogether, this is a first report on the genetic basis of resistance to AurA53- and 
EntL50-like bacteriocins in the interconnection with antibiotics. Bacteria may probably 
cope with these stressors by the accumulation of SNPs resulting in modification of the 
activity of certain enzymes that are, in the physiological state of cells, involved in lipid 
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metabolism. The activity of such modified lipid metabolism DgkB and DxsA enzymes 
may lead to alterations in the composition of the cell envelope that lower the negative 
charge of the cell surface or increase the stability and integrity of the cytoplasmic 
membrane. The second-line protection, which further increases the cell resistance, 
includes the modification of the Bce-like stress response regulatory system proteins such 
as an ABC transporter permease YsaB. These changes enhance cell resistance primarily 
against lipid II cycle and membrane-acting antimicrobials, whereas having no major effect 
on intracellular target antibiotics. Our additional finding that decreased, via SNPs 
accumulation, sensitivity to some antimicrobials (membrane-active bacteriocins and 
antibiotics) results in the concurrently increased vulnerability to other ones (bacitracin, 
carbenicillin, chlortetracycline) is a premise of the design of multidrug preparations with 
tailored composition to reduce the risk of resistance development. 
4. Materials and Methods 
4.1. Bacterial Strains, Plasmids, and Culture Conditions 
The bacterial strains and plasmids used in this study are listed in Table 3. Nisin-
producing L. lactis IBB51 and Lcn972-producing L. lactis IPLA 972 were grown in M17 
medium (BioMaxima, Lublin, Poland) supplemented with 0.5% (wt/vol) glucose (GM17) 
at 30 °C. Wild-type L. lactis LMGT 3419 and its derivates with random mutations or 
deletion of the dxsA gene were grown in Brain Heart Infusion (BHI) medium (Oxoid, 
Hampshire, UK) at 30 °C. L. lactis LMGT 3419- and L. lactis MUT78-derived mutants 
carrying a pIBB-JZK plasmid with the cellobiose-inducible promoter PptcB were grown in 
GM17 medium at 30 °C. To induce transcription of the dxsA gene cloned under PptcB, 
mutants were cultured in the M17 medium supplemented with 1% (wt/vol) cellobiose 
(CM17). E. coli TG1 and EC1000 were grown in Luria–Bertani (LB) medium (Becton, 
Dickinson and Company, East Rutherford, USA) at 37 °C. When appropriate, 
erythromycin (Ery) was added to a final concentration of 75 μg/mL for E. coli or 5 μg/mL 
for L. lactis, and ampicillin (Amp) or tetracycline (Tet) were added to a final concentration 
of 100 or 10 μg/mL, respectively. To prepare soft agar (soft BHI-agar) and agar plates (BHI-
agar, GM17-agar, CM17-agar) liquid media were supplemented with agar (Merck, 
Darmstadt, Germany) to 0.75% and 1.5% (wt/vol), respectively. 
Table 3. Bacterial strains, plasmids, and primers used in this study. 
Strains, Plasmids, Primers Description, Primer Sequence Source * (Reference) 
Strains 
Lactococcus lactis 
IBB51 Nisin producer IBB PAS 
IPLA 972 Lcn972 producer IPLA-CSIC [63] 
LMGT 3419 Indicator strain LMGT 
MUT70, MUT71, MUT72, 
MUT73, MUT78 
LMGT 3419 spontaneous first generation mutants resistant to 
AurA53- and EntL50-like bacteriocins This study 
MUT78.2 LMGT 3419 spontaneous second-generation mutant resistant to 
AurA53- and EntL50-like bacteriocins 
This study 
MUT79c LMGT 3419 strain carrying pGhost9:ΔdxsA This study 
MUT80 LMGT 3419 strain with dxsA deletion This study 
MUT82 LMGT 3419 strain carrying pIBB-JZK This study 
MUT83 LMGT 3419 strain carrying pIBB-JZK:dxsA This study 
MUT84 MUT78 strain carrying pIBB-JZK This study 
MUT85 MUT78 strain carrying pIBB-JZK:dxsA This study 
Escherichia coli 
TG1 Host strain, Δ(hsdMS-mcrB) 5Δ(lac-proAB) supE thi-1 F’(traD36 proAB+lacIqZΔM15) [64] 
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EC1000 Host strain, Kmr, repA+ derivative of MC1000, carrying a single copy of the pWV01 repA gene in glgB [65] 
Plasmids  
pGEMT Ampr, M13ori, linear T-overhang vector Promega 
pGhost9 Emr, repA(Ts) IBB PAS [66] 
pIBB-JZK 
pIBB-JZK:PptcB::dxsA 
Ampr,Tetr, cellobiose-responsive promoter (PptcB) 
Ampr,Tetr, dxsA cloned under the control of PptcB IBB PAS 










* Bacterial strains derived from the Regional Strains and Plasmids Collection of the Institute of Biochemistry and 
Biophysics, Polish Academy of Sciences, Warsaw, Poland (IBB PAS); from the collection of the Laboratory of Microbial 
Gene Technology, Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, 
Norway (LMGT); from the collection of the Dairy Institute of Asturias, Spanish National Research Council, Asturias, Spain 
(IPLA-CSIC) and were obtained in this study. ** BamHI and XhoI restriction sites are underlined. 




Ent7 (MGAIAKLVAKFGWPIVKKYYKQIMQFIGEGWAINKIIDWIKKHI), EntL50 
(MGAIAKLVAKFGWPIVKKYYKQIMQFIGEGWAINKIIEWIKKHI; 
MGAIAKLVTKFGWPLIKKFYKQIMQFIGQGWTIDQIEKWLKRH), WelM 
(MVSAAKVALKVGWGLVKKYYTKVMQFIGEGWSVDQIADWLKRH) and SalC 
(MSALAKLIAKFGYKKIMQLIGEGWTVNQIEKMFK) lyophilized bacteriocins with a 
purity of over 95% were synthesized by a commercial service (PepMic, Suzhou, China). 
Before use, the bacteriocins were dissolved in 0.1% trifluoroacetic acid (TFA) (Sigma, 
Darmstadt, Germany) to a final concentration of 1 mg/mL. Nisin and Lcn972 were 
precipitated from the 0.45 μm pore size filter-sterilized (MilliporeSigma, Burlington, MA, 
USA) supernatants of L. lactis IBB51 and L. lactis IPLA 972 overnight 100 mL cultures, 
respectively. The supernatants were saturated with 30% (wt/vol) ammonium sulfate 
(Sigma, Darmstadt, Germany) and stored for 1 h at 4 °C. The bacteriocin pellets were 
collected after centrifugation at 11,000 rpm for 40 min at 4 °C and dissolved in 1 mL of 
sterile water to the final concentration of 100 ×. The concentration of bacteriocins was 
estimated with Bradford protein assay on ND-1000 Spectrophotometer (NanoDrop 
Technologies, Inc., Wilmington, NC, USA). 
4.3. Selection of BHT-B Resistant Mutants 
Spontaneous resistant mutants were generated by growing L. lactis LMGT 3419 in the 
presence of BHT-B at a concentration of 0.01 mg/mL according to the method described 
before [41]. The level of sensitivity decrease was determined by growing mutants in the 
microtiter plates with serial two-fold bacteriocin dilutions as described before [41]. The 
minimum inhibitory concentration (MIC50) value was presented in μg/mL and defined as 
the lowest concentration of the bacteriocins, at which more than 50% of bacterial growth 
was inhibited. 
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4.4. DNA Isolation and Manipulation 
Genomic DNA of the resistant mutants was isolated using Genomic Mini Kit (A&A 
Biotechnology, Gdynia, Poland) and prepared for sequencing with Nextera XT DNA 
Sample Preparation Kit, Nextera XT Indexing Kit and PhiX Control V3 Kit (Illumina, San 
Diego, CA, USA) according to the manufacturer’s instructions. Sequencing was 
performed using Miseq Sequencer (Illumina, San Diego, CA, USA) and the data were 
analyzed with CLC Genomics Workbench 8.5 (Qiagen, Hilden, Germany). Plasmid DNA 
was isolated using Plasmid Mini Kit or Plasmid Midi AX Kit (A&A Biotechnology, 
Gdynia, Poland). PCR reactions with the Phusion (Thermo Fisher Scientific, Waltham, 
MA, USA) or ExTaq (TaKaRa Bio Inc., Shiga, Japan) polymerases were carried out 
according to the manufacturer’s instructions. Plasmid DNA and PCR products were 
digested with FastDigest enzymes (Thermo Fisher Scientific) and ligated with T4 DNA 
ligase (Thermo Fisher Scientific, Waltham, MA, USA). DNA fragments from PCR, 
restriction digest, or agarose gel were purified using Wizard® SV Gel and PCR Clean-Up 
System (Promega, Fitchburg, MA, USA). The translation of nucleotide sequences to 
protein sequences was done with an Expasy translate tool [67] 
(https://web.expasy.org/translate/). Protein sequences were aligned using the Clustal 
Omega program [68] (https://www.ebi.ac.uk/Tools/msa/clustalo/). Template-based 
tertiary structures of DxsA and YecE were modeled with the I-TASSER server [69] 
(https://zhanglab.ccmb.med.umich.edu/I-TASSER/). 1-deoxy-D-xylulose 5-phosphate 
synthases from D. radiodurans R1 and E. coli K12 (PDB/NCBI accession nos 
2O1X/WP_010888114.1 and 2O1S/WP_074526961.1, respectively) and soluble 
diacylglicerol kinases from S. aureus MRSA252 and E. faecalis V583 (PDB accession nos 
2QV7/WP_001231458.1 and 4WER/WP_002362274.1, respectively) were used as templates 
of the highest significance for DxsA and YecE, respectively. Predicted tertiary structures 
were visualized using PyMOL Molecular Graphics System, Version 2.0 (Schrödinger, 
LLC, New York, NY, USA). 
4.5. Construction of the Deletion Mutant 
Knockout of the dxsA gene was performed using the homologous recombination 
method. First, DNA fragments upstream (UP) and downstream (DN) of the dxsA gene 
were amplified with Phusion, and DxsAUPfor/rev and DxsADNfor/rev primers pairs 
(Table 3). Then, purified PCR products were digested with BamHI and ligated. An 
additional PCR with ExTaq and DxsAUPfor/DxsADNrev primers was performed to 
amplify ligated fragments. PCR product was purified from the agarose gel and cloned 
into pGEM-T Easy vector (Promega) by TA cloning. Ligated vector was transformed into 
E. coli TG1 and the sequence of the dxsA was verified by sequencing with 1224/1233 
primers (Table 3). Next, the recombinant vector was digested with ApaI and NotI, the 
insert was purified from the agarose gel and cloned into pGhost9 vector. Ligated vector 
was transformed sequentially into E. coli EC1000 and L. lactis LMGT 3419. The presence 
of the insert was confirmed by PCR with ExTaq and pGhfor/rev primers (Table 3). Double 
cross-over event was forced by 103-fold dilution of the L. lactis overnight culture in BHI 
medium supplemented Ery (5 μg/mL) and incubation for 1.5 h at 30°C and 3.5 h at 37°C. 
To select integrants, culture was streaked on BHI-agar plates supplemented Ery (5 μg/mL) 
and incubated at 37 °C. To remove the integrated vector, single colonies were passaged 
on BHI-agar plates and incubated at 30 °C. The deletion of the dxsA gene was confirmed 
by colony PCR with ExTaq and DxsAOUTfor/rev primers (Table 3). To cure the vector, 
the deletion mutant was cultivated in the absence of antibiotics at 30 °C. The absence of 
the pGhost9 was confirmed by colony PCR with ExTaq and pGhfor/rev primers, and tests 
of susceptibility to Ery. 
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4.6. Construction of the Expression Mutants 
Expression of the dxsA gene was performed using the low-copy pIBB-JZK with 
cellobiose-inducible promoter PptcB [70]. First, dxsA was amplified using Phusion and 
DxsAfor/rev primers (Table 3). PCR product was purified and cloned into pIBB-JZK under 
PptcB using the BamHI and XhoI. Then, the ligated vector was transformed into E. coli 
EC1000 and the sequence of the dxsA was verified by sequencing with pIBB-JZKfor/rev 
primers (Table 3). Finally, the recombinant vector (pIBB-JZK:PptcB::dxsA) was 
transformed into L. lactis LMGT 3419 and L. lactis MUT78 resulting in the L. lactis MUT83 
and L. lactis MUT85, respectively. The presence of the insert was confirmed by PCR with 
ExTaq and pIBB-JZKfor/rev primers. 
4.7. Antibiotic Susceptibility Testing 
Wild-type L. lactis LMGT 3419 and its derivates with random mutations or dxsA-
deletion were streaked onto BHI-agar plates while L. lactis LMGT 3419- and L. lactis 
MUT78-derivates with pIBB-JZK were streaked onto CM17-agar plates supplemented Tet 
(10 μg/mL). Plates were incubated overnight at 30 °C. Suspensions of the strains were 
prepared in 0.85% saline and the turbidity was adjusted to that of McFarland 1.0 standard 
(bioMérieux, Marcy-l’Étoile, France). Then, the solutions were spread evenly over the 
surface of ISO-BHI-agar plates (Oxoid, Hampshire, UK) or CM17-agar plates 
supplemented Tet (10 μg/mL) and disks or strips impregnated with antibiotics were 
applied onto the plates. All antibiotic strips were purchased from bioMérieux except 
bacitracin strips that were purchased from Liofilchem (Roseto Degli Abruzzi, Italy). 
Carbenicillin and chlortetracycline disks were purchased from Oxoid and Čaderský-
Envitek (Brno, Czech Republic), respectively. The plates were incubated for 48 h at 30 °C 
and then the inhibition zones were measured (mm). The MIC value (μg/mL) was defined 
as the concentration of the antibiotic at which the edge of the inhibition ellipse intersects 
the strip. Resistance to gramicidin (Sigma, Darmstadt, Germany) was determined using 
microtiter plates with serial two-fold gramicidin dilutions as described before [41]. 
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